Premetrexed (Alimta) + Carboplatin
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Inoperable Non Small Cell Lung Cancer
Conditions
Inoperable Non Small Cell Lung Cancer
Trial Timeline
Apr 1, 2006 → Oct 1, 2009
NCT ID
NCT00330044About Premetrexed (Alimta) + Carboplatin
Premetrexed (Alimta) + Carboplatin is a phase 1 stage product being developed by Eli Lilly for Inoperable Non Small Cell Lung Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00330044. Target conditions include Inoperable Non Small Cell Lung Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00330044 | Phase 1 | Completed |
Competing Products
10 competing products in Inoperable Non Small Cell Lung Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eribulin Mesylate | Eisai | Pre-clinical | 23 |
| Fulvestrant + Capivasertib + Placebo | AstraZeneca | Phase 3 | 77 |
| Selumetinib | AstraZeneca | Pre-clinical | 23 |
| Tomudex | AstraZeneca | Phase 2 | 52 |
| Cisplatin + Gemcitabine + Selumetinib | AstraZeneca | Phase 1 | 33 |
| Capivasertib + Fulvestrant + Palbociclib + Ribociclib + Abemaciclib | AstraZeneca | Phase 3 | 77 |
| Drug (including placebo) | Merck | Phase 1 | 33 |
| BEZ235 + Paclitaxel | Novartis | Phase 1/2 | 41 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 41 |
| dacomitinib hydrate | Pfizer | Pre-clinical | 22 |